Fri.Aug 02, 2024

article thumbnail

Pancreatic Cancer Dendritic Cell Vaccine Receives FDA Fast Track Designation

Drug Topics

The technology from Diakonos Oncology initiates a natural immune response that targets and eliminates cancer cells by activating cytotoxic TH1 cell signaling pathways.

article thumbnail

BLZ945 Offers New Possibilities for Eradicating HIV From the Brain

Pharmacy Times

The experimental drug successfully reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain.

153
153
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Opinion: The coronavirus lab leak hypothesis is damaging science

STAT

Where and when the Covid-19 pandemic began — in Wuhan, China in late 2019 — is well known. How it began is a matter of heated controversy. There are two competing hypotheses, one of which is hindering the process of scientific discovery and could hold back the development of vaccines and other antiviral agents in the U.S. The zoonosis hypothesis proposes that SARS-CoV-2, the virus that causes Covid-19, was naturally transmitted from an animal to one or more humans in a so-called we

Vaccines 145
article thumbnail

2-Drug Regimen Shows Comparable Effectiveness With 3-Drug Regimen to Treat HIV-1

Pharmacy Times

Dolutegravir/lamivudine was non-inferior to bictegravir/emtricitabine/tenofovir alafenamide fumarate, meeting the study’s primary end point.

139
139
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: UnitedHealth and HCA clash over hospital chain’s rates in ‘battle of the giants’

STAT

Contract disputes between hospitals and health plans have become routine, but they tend to be local , affecting a handful of hospitals and the people in the surrounding communities. This latest one is different. It involves the country’s biggest private health insurer, UnitedHealthcare, and its biggest hospital chain, HCA Healthcare. If they can’t strike a deal on prices by Sept. 1, 38 hospitals and their affiliated physician groups and surgery centers across four states — T

Hospitals 144
article thumbnail

CDC Recommends International Travelers Receive MMR Vaccination 2 Weeks Prior to Travel

Pharmacy Times

The CDC says that even if travel is less than 2 weeks away, unvaccinated individuals should still receive a dose of the measles, mumps, and rubella vaccine for protection against the disease.

Vaccines 139

More Trending

article thumbnail

Intravenous Immunoglobulin Effective in Achieving Viral Clearance, Neutralizing Several SARS-CoV-2 Variants

Pharmacy Times

In an analysis of 16 immunocompromised patients with COVID-19, intravenous immunoglobulin was effective and associated with clinical cure.

139
139
article thumbnail

What we do and don’t know about the shortage of blood culture bottles

STAT

In July, federal health officials warned hospitals that there would be a critical shortage of blood culture bottles that will stretch into September. Blood culture bottles are key in diagnosing sepsis, a deadly infection of the bloodstream caused by a number of different bacteria. According to the Centers for Disease Control and Prevention, about half of U.S. labs get their bottles from a company known as BD, the supplier that is in shortage, meaning that the shortage could have big implications

article thumbnail

Vertex lifts sales guidance as launch of gene therapy Casgevy picks up steam

Fierce Pharma

As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. | As of mid-July, around 20 patients completed the first step of Casgevy treatment by having their cells collected, up from five patients during the first quarter.

138
138
article thumbnail

Opinion: ACL tears in women: Too many injuries and too little research

STAT

Some of the world’s finest athletes were sidelined by a torn anterior cruciate ligament (the ligament that helps stabilize the knee joint) long before the torch was lit for the Paris Olympics. The list of women competitors with ACL tears is stunning. Basketball player Cameron Brink , rugby medalist Shiray Kaka, gymnast Asia D’Amato, and several other athletes will not be competing because of this all-too-common, season-ending, and potentially career-ruining injury.

138
138
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

FDA signs off on Adaptimmune's Tecelra as the first engineered cell therapy for a solid tumor

Fierce Pharma

Adaptimmune has won accelerated FDA approval | Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma which becomes the first engineered cell therapy for a solid tumor and the first new treatment in the indication in more than a decade.

FDA 133
article thumbnail

STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer

STAT

LONDON — U.S. regulators have authorized a cutting-edge treatment relying on T cells for a rare cancer that arises in the body’s soft tissues, extending the power of immunotherapies to difficult-to-reach sarcomas.   The medicine, called Tecelra and developed by Adaptimmune Therapeutics, is what’s known as a T cell receptor therapy.

FDA 133
article thumbnail

Expert: The Definition of Alzheimer Disease is Shifting From Clinical to Biological

Pharmacy Times

Edward B. Lee, MD, PhD, also describes how understanding Alzheimer disease requires the integration of multiple fields including genetics, pathology, epidemiology, pharmacology, and physiology.

132
132
article thumbnail

Opinion: Address liquid biopsy disparities today to ensure equity in outcomes tomorrow

STAT

The promise of scientific and medical innovation often comes with a downside: improvements in care benefit some people, but not all. Without concerted effort, that is exactly what could happen with liquid biopsy — an evolving technology aimed at improving cancer care using just a few milliliters of blood or other body fluids. Liquid biopsy technologies are maturing at a rapid pace.

132
132
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

FDA Approves MAGE-A4 IHC 1F9 pharmDx as Diagnostic Tool in Patients With Synovial Sarcoma

Pharmacy Times

The diagnostic tool can aid the identification of patients with synovial sarcoma who may be eligible for treatment with newly approved afamitresgene autoleucel.

FDA 123
article thumbnail

STAT+: 23andMe board rejects co-founder Anne Wojcicki’s offer to take company private

STAT

A special committee of the board of directors of 23andMe rejected an offer from the company’s co-founder and CEO, Anne Wojcicki, to take the company private. In a letter made public Friday, the board said that Wojcicki’s proposal failed to offer a premium to 23andMe’s current stock price, did not have committed financing from other investors, and came with other conditions it rejected.

130
130
article thumbnail

Lilly gets first heart outcomes readout with tirzepatide

pharmaphorum

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on cardiovascular outcomes with the drug.

118
118
article thumbnail

Moderna is still in a Covid hangover

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning and happy Friday. We discuss a new innovative immunotherapy, and we take a look at some of the earnings highlights yesterday.

129
129
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Q&A: Understanding Benefits, Managing Adverse Effects of GLP-1 Receptor Agonists

Drug Topics

These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.

112
112
article thumbnail

Building a future-ready digital workforce in pharma

pharmaphorum

Discover how digital transformation is reshaping the pharmaceutical industry and learn how to prepare your workforce for the future with this guide on building a future-ready digital workforce in pharma.

111
111
article thumbnail

Benefits of GLP-1s Transcend Simple Weight Loss for Individuals With Overweight, Obesity, and Comorbidities

Drug Topics

Losing even 5% of body weight can improve comorbid conditions and other health complications for individuals with overweight and obesity.

112
112
article thumbnail

What pharma has learned from AI

PharmaVoice

As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.

111
111
article thumbnail

Managing “Class Action” Adverse Effects Crucial for GLP-1 Medication Adherence

Drug Topics

Some patients may have difficulty managing the gastrointestinal adverse effects associated with GLP-1 therapies.

112
112
article thumbnail

Fierce Pharma Asia—Merck's surprise hiccup in China; Leqembi's slow ramp; Lawmakers' new biosecurity target

Fierce Pharma

Merck is trying to determine the reasons behind the surprise decline of Gardasil in China. Eisai and Biogen's Leqembi was rejected by European authorities amid a continued slow sales ramp. | Merck is trying to determine the reasons behind the surprise decline of Gardasil in China. Eisai and Biogen's Leqembi was rejected by European authorities amid a continued slow sales ramp.

110
110
article thumbnail

Pharmacists’ Ability to Close Gap in Delivery of Oral Anticoagulation Therapy

Drug Topics

Researchers aimed to discover whether pharmacist-led delivery of oral anticoagulation therapy can lead to an increase in stroke risk reduction for patients with actionable atrial fibrillation.

112
112
article thumbnail

Closed and Collaborative: Mergers, acquisitions, and partnerships in June 2024

pharmaphorum

Explore the latest mergers, acquisitions, and partnerships in June 2024 involving LucidHealth, Syncona, Spur Therapeutics and more. Stay updated on the business collaborations shaping the industry.

108
108
article thumbnail

FDA Grants Accelerated Approval to First Engineered Cell Therapy for Synovial Sarcoma

Drug Topics

Afami-cel is the first new treatment for synovial sarcoma in more than 10 years, ending a long-standing therapeutic gap.

FDA 112
article thumbnail

What 'The Next Berlin Patient' and a PrEP’s 100% efficacy mean for HIV drug development

Fierce Pharma

This week on “The Top Line,” we discuss two studies in HIV research that were presented at the 25th International AIDS | This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany.

108
108
article thumbnail

Researchers Identify a Potential Therapeutic Target for Multiple Sclerosis

Pharmacy Times

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

107
107
article thumbnail

Otsuka Pharmaceutical to Purchase Jnana Therapeutics

Pharmaceutical Commerce

In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.

105
105
article thumbnail

Can you drink while taking lisinopril?

The Checkup by Singlecare

Lisinopril is a common medication used for managing high blood pressure (hypertension) and heart failure. Healthcare providers also prescribe lisinopril to improve survival after a heart attack. It’s usually taken daily, on a long-term basis, to manage symptoms. If an evening glass of wine or happy hour with friends was part of your routine before being diagnosed, you may be wondering, is it ever safe to drink alcohol while taking this prescription?

article thumbnail

FDA clears Adaptimmune T-cell therapy for soft tissue cancer

pharmaphorum

FDA has approved Adaptimmune's Tecelra for synovial sarcoma, the first engineered T-cell therapy for solid tumours

FDA 105
article thumbnail

Pharma Pulse 8/2/24: Overcoming Challenges to Drive Digital Customer Engagement, Mental Health Leaves of Absence Continue to Proliferate & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

105
105